

Journal of Mind and Medical Sciences

Volume 7 | Issue 2

Article 13

2020

The use of NDYAG laser combined with pulsed light in the treatment of rosacea

Valeriu Ardeleanu

OVIDIUS UNIVERSITY, FACULTY OF MEDICINE, CONSTANTA, ROMANIA

Lavinia Alexandra Moroianu

DUNĂREA DE JOS UNIVERSITY, 47 DOMNEASCA STREET, GALATI, ROMANIA

Vlad Denis Constantin

CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY, BUCHAREST, ROMANIA

Petrisor Banu

CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY, BUCHAREST, ROMANIA

Florin Silviu Groseanu

CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY, BUCHAREST, ROMANIA

Follow this and additional works at: <https://scholar.valpo.edu/jmms>

See this page for additional authors



Part of the [Dermatology Commons](#), [Plastic Surgery Commons](#), [Primary Care Commons](#), and the [Surgery Commons](#)

Recommended Citation

Ardeleanu, Valeriu; Moroianu, Lavinia Alexandra; Constantin, Vlad Denis; Banu, Petrisor; Groseanu, Florin Silviu; Paunica, Ioana; Dascalu, Ana Maria; and Tatu, Alin Laurentiu (2020) "The use of NDYAG laser combined with pulsed light in the treatment of rosacea," *Journal of Mind and Medical Sciences: Vol. 7 : Iss. 2 , Article 13.*

DOI: 10.22543/7674.72.P206211

Available at: <https://scholar.valpo.edu/jmms/vol7/iss2/13>

This Research Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.

The use of NDYAG laser combined with pulsed light in the treatment of rosacea

Authors

Valeriu Ardeleanu, Lavinia Alexandra Moroianu, Vlad Denis Constantin, Petrisor Banu, Florin Silviu Groseanu, Ioana Paunica, Ana Maria Dascalu, and Alin Laurentiu Tatu

The use of NDYAG laser combined with pulsed light in the treatment of rosacea

Valeriu Ardeleanu^{1,2,3,4,*}, Lavinia Alexandra Moroianu^{2,5,*}, Vlad Denis Constantin⁶, Petrisor Banu⁶, Florin Silviu Groseanu⁶, Ioana Paunica⁶, Ana Maria Dascalu^{6,7}, Alin Laurentiu Tatu²

¹OVIDIUS UNIVERSITY, FACULTY OF MEDICINE, CONSTANTA, ROMANIA

²DUNĂREA DE JOS UNIVERSITY, 47 DOMNEASCA STREET, GALATI, ROMANIA

³GENERAL HOSPITAL CFR, 4-6 ALEXANDRU MORUTZI STREET, GALATI, ROMANIA

⁴ARESTETIC CLINIC, 78 BRAILEI STREET, BRĂA, GALATI, ROMANIA

⁵ELISABETA DOAMNA PSYCHIATRY HOSPITAL, 290 TRAIAN STREET, GALATI, ROMANIA

⁶CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY, BUCHAREST, ROMANIA

⁷DEPARTMENT OF OPHTHALMOLOGY, EMERGENCY UNIVERSITY HOSPITAL BUCHAREST, ROMANIA

ABSTRACT



Rosacea is a chronic inflammatory skin disease with a complex pathogenesis that mainly affects the central part of the face, with a global incidence of 5.46%. The present study was performed on a group of 68 patients with rosacea 1 and 2 subtypes, patients between 34-63 years old. The treatments were performed using a Cutera Xeo laser, using 2 types of probes: NdYag 1064nm for telangiectasias and LimeLight 520-1100nm for diffuse facial erythema, papules, and pustules, having an 10x30mm window. For patients with diffuse facial erythema, etc., the optimal number of sessions was between 3 and 6 with or without anesthetic cream, using energies between 14-19J / cm. The average recovery time was 5 days. Registered effects included bruises, pustules, burning sensation, transient stinging, and hypopigmentation. For patients with telangiectasia, the optimal number of sessions was two, performed at an average interval of once per month/ monthly.

Category: Original Research Paper

Received: March 18, 2020

Accepted: June 02, 2020

Keywords:

rosacea, cuperosis, NDYAG laser, intense pulsed light

***Corresponding author:**

Lavinia Alexandra Moroianu,

Dunărea de Jos University, Elisabeta Doamna Psychiatry Hospital, 47 Domneasca Street, Galati, Romania;

E-mails: lavinia_anton88@yahoo.com,
valeriu.ardeleanu@gmail.com

Introduction

Rosacea is a chronic inflammatory disease of the skin with a complex pathogenesis that mainly affects the central part of the face [1]. The term “rosacea” was introduced in the 19th century by Thomas Bateman [2]. The disease affects both sexes and can be found at any age, but frequently, the debut of the disease occurs after the age of 30 years.

In women, there was an increased incidence of erythematotelangiectatic and papulopustular rosacea, in which the debut was recorded after the age of 40 [3]. The incidence of the disease according to the latest reported statistical data is between 0.09 and 22.41%, with an average of 5.46% amongst world populations [4;5], reaching up to 10% among the Caucasian population [6]. The disease is also more common for Fitzpatrick III and IV phototypes, and lower for V and VI phototypes [6]. From a clinical point of view, the disease is manifested by facial erythema (transient or persistent), telangiectasia, edema,

papules and pustules, burning sensation, stinging, pain or itching; patients may show one or more signs and symptoms [7]. There are also cases in which patients are completely asymptomatic, the disease having only facial skin signs [8]. The disease has a sinusoidal evolution, with periods of remission and exacerbation. It is important to emphasize the role of Demodex Folliculorum in the appearance of Rosacea, because its number is increased in confirmed patients compared to patients without rosacea, questioning whether its multiplication directly or indirectly produces rosacea, or alternatively whether rosacea is favorable ground for its multiplication. Studies show that Demodex Folliculorum can be present and multiplied without producing rosacea, only spinulosis, including areas other than the central facial area. Sometimes its presence and associated endosymbiont bacteria, described in the literature, can produce rosacea or demodeciosis with inflammatory elements, objectified through spectrometric bacteriological methods, imagistic- ex: VISIA dermoscopy [9-12].

Rosacea was classified into 4 main subtypes: erythromethelothectectic (subtype 1), papulopustular (subtype 2), phytomatous (subtype 3), and ocular (subtype 4), granulomatous rosacea being considered a variant/type of rosacea rather than a subtype. Since 2017, the classification of rosacea is based on phenotypes and for the diagnosis of rosacea, at least one diagnosis or two major phenotypes are required [6].

The diagnostic phenotypes for rosacea are:

- Persistent erythema of the central face area that worsens with some triggers
- Phytomatic changes (most commonly rhinophyma)

The major phenotypes for rosacea are:

- Transient facial erythema of the central face
- Inflammatory papules and pustules
- Telangiectasias
- Ocular changes: blepharitis, keratitis, conjunctivitis, ocular telangiectasias

Minor phenotypes for rosacea are:

- Burning sensation
- Stings
- Edema
- Dryness [13].

Also, a particular type of rosacea is the secondary one, induced by the prolonged use of cutaneous dermatocorticoids or calcineurin inhibitors [14-17].

Materials and Methods

The present study is based on 68 patients, with the age between 34-63 years with a prevalence of women (76%). The inclusion criteria were: patients with rosacea subtypes 1 and 2. Exclusion criteria were: patients with rosacea subtypes 3 and 4.

The treatments were performed with the Cutera Xeo laser, using 2 probes: NdYag 1064 nm and LimeLight 520-1100 nm, with a 10x30 mm window. The protocol used in the study was:

- for telangiectasia (cuperotic stage of the disease), NdYag treatment was applied, 1 session every 1-2 months. The working parameters were: 3 mm spot, time 15-25 ms, energy 110-130 J / cm².
- for diffuse facial erythema, papules, and pustules, the LimeLight probe was applied, 1 session of 3-4 weeks, program A (vascular) and an energy of 15-19 J / cm².

Since the two conditions usually exist simultaneously, the following steps have been followed: LimeLight sessions were done every 3-4 weeks, followed by the 2 NdYag sessions.

The treatments were performed exclusively between October and May of the same year. For maintenance, we

recommend 1-2 sessions of LimeLight annually during winter. Post-procedure, all patients received recommendations to use a mixture of cream with a protection factor of at least 50% during the entire length of treatment, to avoid exposure to excessive heat such as sauna, sun, or solarium exposure, and to avoid alcohol consumption.

Results

For patients with diffuse facial erythema, papules, etc., the optimal number of sessions with the LimeLight probe was 4, at intervals of 3-4 weeks. The maximum number of sessions was 6, the fewest 3. Most treatments were performed without anesthetic cream though some patients wanted to use the cream. The degree of discomfort during the procedure was medium, and the treatments were started from energies of 14-15 J/cm² and increased progressively, from session to session, to energies of 18-19 J/cm². The average recovery time was 5 days, during which the patient presented with severe edema. As side effects, there were small bruises, small pustules, burning sensation, and transient stinging. As complications, in 3 patients there were observed areas of hyperpigmentation, partially remitted. We did not record any post-procedure scars. Although after the first sequence of LimeLight procedure, many patients said they would stop treatment, ultimately all patients completed the treatment.

For patients with telangiectasia, the optimal number of sessions was 2, performed on average monthly. Telangiectasia disappeared completely after these 2 sessions. As for complications, in two cases there were small excavations in the nose, instead of blood vessels, almost imperceptible but permanent. As an advantage, however, a reduction in the volume of the nose was observed. The area of predilection treated was that of the nose, followed by the chin and only in a few cases by the zygomatic areas. It did not require recovery time and the treatment was well tolerated by all patients. No local anesthesia was required.

Discussions

It is known that rosacea has negative effects on quality of life, including psychosocial well-being in people with mild, moderate, or severe erythema. However, this impact on self-perception and emotional, social, and general well-being is significantly higher in people with severe erythema [18]. Thus, we paid special attention to improving the quality of life of these patients [19]. In this case, the end results were very positive, with an excellent aesthetic result and with complete remission of the symptoms in most cases. The degree of satisfaction of the patients was very good, with the return to normal of their self-confidence and well-being.

Rosacea treatment is not standardized; we are still seeking optimal treatment protocols. One of the usual therapeutic approaches for rosacea is based on reducing inflammation, using various drugs and substances such as doxycycline [20], metronidazole [21], topical azelaic acid [22], sodium sulfacetamide [23] and calcineurin inhibitors, [24], ivermectin, pimecrolimus, retinoids, permethrin, benzoyl peroxide, erythromycin, and dapsone [25]. Utilization of serine protease inhibitors is considered an emerging therapy for rosacea [26]. Isotretinoin has also been used in patients with papulopustular subtype rosacea [27]. But this approach is useful only in the early stages, with the improvement of symptoms, though with suboptimal aesthetic results and in most cases with a non-negligible toxicity for the body, with gastrointestinal disorders or increased photosensitivity.

Recently, photodynamic therapy (PDT) has increasingly gained ground [28,29], sometimes in association with other treatments such as methyl ester aminolevulinic acid (MAL) [30]. Furthermore, an *in vitro* study performed on mouse skin showed that the most effective wavelengths are 630 nm and 940 nm, which decrease some mediators of rosacea inflammation, such as cathelicidin (LL-37), TLR2 and kallikreins (KLKs) [31]. Photodynamic therapy also interacts with the skin microbiome [32]. Research is currently continuing on the effectiveness of blue and red light on the skin's microflora in patients with rosacea and acne patients [33].

Different types of lasers with wavelengths between 400-1400 nm are used to treat diffuse facial erythema. Thus, in addition to intensely pulsed light that involves a wide spectrum of wavelengths, 595 nm colored pulse lasers (PDL) are also used. Furthermore, the use of intensely pulsed light at a wavelength of 560 nm is as effective as the PDL laser in the treatment of facial erythema, but with much lower side effects than the PDL laser and with a shorter recovery time [32], this being the main consideration for using a laser with intense pulsed light and not a PDL. Most people who present with rosacea are active people who cannot afford long periods of recovery. [34].

For the treatment of telangiectasias, the range of lasers used is larger. However, the principle underlying their functioning in the case of vascular lesions is the same, namely the absorption of energy by hemoglobin [35]. Thus, the lasers used to treat telangiectasia are: 1064 nm Neodymium-doped, yttrium – aluminum – garnet (Nd-YAG), 532 nm Potassium-Titanium-Phosphate (KTP), 595 nm PDL, dual wavelength long-pulsed 775 nm alexandrite/1,064 nm neodymium: yttrium-aluminum (LPAN) [36]. The most used lasers, however, remain by far NdYag 1064 nm and PDL 595 nm.

As far as the approach order of rosacea lesions, all authors prefer to use in the first stage intense pulsed light

(IPL) followed by the use of NdYag or PDL lasers to close telangiectasia [25], an approach that we have used in our clinic. NdYag lasers have the advantages over PDL of less pain production, shorter recovery time, and fewer complications, yet with results that are comparatively the same [25], and thus, the basis for choosing the NdYag laser and not a PDL in the treatment of telangiectasia. The efficiency of NdYag lasers can be increased by combining it with topical substances based on retinoic acid (some authors find this increases potency up to 47%) or vitamin C or D [37-39]. In recent years, radiofrequency devices have been used to treat telangiectasia, but thus far, results are not promising, with radiofrequency tending to be overrated as a good-for-everything technique [40].

Recently, Botox has been introduced as a therapeutic method in the treatment of rosacea: it seems its actions take place through the nervous system by lowering local vascularity, but the mode of action and efficacy are yet to be fully evaluated [41].

The factors that lead to the appearance of rosacea are not fully elucidated. Some innate or acquired immune dysfunctions are often associated with several neurovascular dysfunctions, with a genetic component underlying the appearance of rosacea [42]. These dysfunctions are directly or indirectly associated Demodex Folliculorum (DF) (through its own bacteria endosymbiosis, or other bacteria unrelated to DF such as Staphylococcus), epidermidis, ultraviolet (UV) radiation, extreme temperatures, stress, congestive foods, and the presence of metabolic syndrome or diabetes mellitus [38-41]. DF has been shown to have Bacillus bacteria endosymbionts such as Bacillus Oleronius, Bacillus Pumilus, Bacillus simplex, Cereus or Corynebacterium kroppenstedtii [44-46].

DF, either directly or through its endosymbionts, can trigger the cascade of immunologically active peptides by interacting directly or indirectly with various structures, including receptor type. It has also been found that some skin receptors exhibit enhanced receptivity, such as Toll-like receptor (TLR) 2, nucleotide-binding oligomerization domain (NOD)-like receptor, and transient vanilloid receptor potential (TRPV4). Activation of these receptors causes the production of immune peptides (eg, LL-37) and various cytokines and chemokines, which induce a variety of inflammatory reactions [47]. The TLR2 receptor can also activate kappa B nuclear transcription factor (NF-kB), further accentuating inflammation [48]. Implicitly, they will also cause neurovascular changes. Mast cells also participate in the appearance of rosacea by increasing inflammation, angiogenesis, and fibrosis [49]. More recently, rosacea and other skin diseases such as psoriasis and atopic dermatitis have been linked to intestinal dysbiosis, although the role of the association of

Helicobacter pylori infection or SIBO-small intestinal bacterial overgrowth is still debated [50]. However, the cascade of inflammatory reactions and triggers is much wider. Thus, keratinocytes will release cathelicidin, vascular endothelial growth factor and endothelin-1, endothelial cells will release nitric oxide, mast cells will release cathelicidin and matrix metalloproteinases, macrophages will release interferon-gamma, tumor necrosis factor, matrix metalloproteinase and interleukin-26 and in addition, all these factors can communicate directly with the cutaneous nervous system through active neurovascular neuropeptides. The consequences of these many pathophysiological changes over the long term are: vasodilation, glandular hyperplasia, and fibrosis. The presence of rosacea may contraindicate or limit the indications for some dermato-cosmetic treatments such as chemical peels or hyaluronic acid treatments [51-53]. It may also limit the use of other types of lasers for various dermatological conditions that induce local vasodilation; in these cases, the order of treatment must be analyzed [54-55].

Conclusions

Rosacea is a dermatological condition with multifactorial etiology. Its clinical forms require complex treatments on the one hand, combined, both topical and systemic but also by using NdYag laser devices and intense pulsed light; on the other hand, the treatments are adapted to the particularities and comorbidities associated with rosacea in our patients.

This paper presents the results of the treatments performed, with the help of a Cutera Xeo laser, using 2 probes: NdYag 1064 nm and LimeLight 520-1100 nm, with a window of 10x30 mm. The maximum number of sessions was 6, the minimum was 3. Most treatments were made without anesthetic cream though some patients wanted anesthetic cream. The degree of discomfort during the procedure was medium, and treatments were started from energies of 14-15 J/cm² and increased progressively, from session to session, to energies of 18-19 J/cm². The average recovery time was 5 days, during which the patient presented severe edema. As side effects, there were small bruises, small pustules, burning sensation, and transient stinging. As complications there were registered, in 3 patients, areas of hyperpigmentation which partially remitted. We did not observe post-procedure scars. Rosacea treatment remains to be individualized according to the needs and status of patients.

Conflict of interest disclosure

There are no known conflicts of interest in the publication of this article. The manuscript was read and approved by all authors.

Compliance with ethical standards

Any aspect of the work covered in this manuscript has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

References

1. Yuan X, Huang X, Wang B, et al. Relationship between rosacea and dietary factors: A multicenter retrospective case-control survey. *J Dermatol.* 2019;46(3):219-225. doi:10.1111/1346-8138.14771
2. Plewig G, Kligman AM. History of Acne and Rosacea. Acne And Rosacea. Berlin: Springer; 2000. <https://www.springer.com/gp/book/9783642640964>
3. Rainer BM, Fischer AH, Luz Felipe da Silva D, Kang S, Chien AL. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. *J Am Acad Dermatol.* 2015;73(4):604-608. doi:10.1016/j.jaad.2015.07.009.
4. Parisi R, Yiu ZZN. The worldwide epidemiology of rosacea. *Br J Dermatol.* 2018;179(2):239-240. doi:10.1111/bjd.16788
5. Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. *Br J Dermatol.* 2018;179(2):282-289. doi:10.1111/bjd.16481
6. Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. *J Am Acad Dermatol.* 2018;78(1):148-155. doi:10.1016/j.jaad.2017.08.037
7. Engin B, Özkoca D, Kutlubay Z, Serdaroğlu S. Conventional and Novel Treatment Modalities in Rosacea. *Clin Cosmet Investig Dermatol.* 2020;13:179-186. Published 2020 Feb 20. doi:10.2147/CCID.S194074.
8. Tuta LA, Iorga I, Azis O, Voinea F. End-of-life Care in Elderly Patients with End-Stage Renal Disease – Ethical and Clinical Issues. SGEM 2015, Book 1: Psychology and Psychiatry, Sociology and Healthcare, Education Conference Proceedings. 2015;1:487-493.
9. Tatu AL, Cristea VC. Pityriasis Folliculorum of the Back Thoracic Area: Pityrosporum, Keratin Plugs, or Demodex Involved?. *J Cutan Med Surg.* 2017; 21(5):441. doi:10.1177/1203475417711114
10. Tatu AL, Cristea VC. Unilateral Blepharitis With Fine Follicular Scaling. *J Cutan Med Surg.* 2017; 21(5):442. doi:10.1177/1203475417711124
11. Tatu AL. Umbilicated Blue-Black Lesion on the Lateral Thorax. *J Cutan Med Surg.* 2017; 21(3):252. doi:10.1177/1203475417694859

12. Tatu AL, Clatici VG, Nwabudike LC. Rosacea-like demodicosis (but not primary demodicosis) and papulopustular rosacea may be two phenotypes of the same disease - a microbioma, therapeutic and diagnostic tools perspective. *J Eur Acad Dermatol Venereol.* 2019;33(1):e46-e47. doi:10.1111/jdv.15166
13. Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. *Br J Dermatol.* 2017;176(2):431-438. doi:10.1111/bjd.15122.
14. Tatu AL. Topical Steroid Induced Facial Rosaceiform Dermatitis. *Acta Endocrinol (Buchar).* 2016;12(2):232-233. doi:10.4183/aeb.2016.232
15. Tatu AL, Ionescu MA, Clatici VG, Cristea VC. *Bacillus cereus* strain isolated from Demodex folliculorum in patients with topical steroid-induced rosaceiform facial dermatitis. *An Bras Dermatol.* 2016; 91(5): 676-678. doi: 10.1590/abd1806-4841.20165214
16. Tatu AL, Clăti V. Some correlations between the clinical and dermoscopic features of steroid induced facial dermatitis. *J Am Acad Dermatol.* 2015; 72(5)Suppl 1:AB91.
17. Tatu AL, Ionescu MA, Nwabudike LC. Contact Allergy to Topical Mometasone Furoate Confirmed by Rechallenge and Patch Test. *Am J Ther.* 2018;25(4):e497-e498. doi:10.1097/MJT.0000000000000581
18. Baldwin HE, Harper J, Baradaran S, Patel V. Erythema of Rosacea Affects Health-Related Quality of Life: Results of a Survey Conducted in Collaboration with the National Rosacea Society. *Dermatol Ther (Heidelb).* 2019;9(4):725-734. doi:10.1007/s13555-019-00322-5.
19. Tofolean DE, Mazilu L, Stăniceanu F, et al. Clinical presentation of a patient with cutis laxa with systemic involvement: a case report. *Rom J Morphol Embryol.* 2015;56(3):1205-1210.
20. Di Nardo A, Holmes AD, Muto Y, et al. Improved clinical outcome and biomarkers in adults with papulopustular rosacea treated with doxycycline modified-release capsules in a randomized trial. *J Am Acad Dermatol.* 2016;74(6):1086-1092. doi: 10.1016/j.jaad.2016.01.023.
21. Cardwell LA, Alinia H, Moradi Tuchayi S, Feldman SR. New developments in the treatment of rosacea - role of once-daily ivermectin cream. *Clin Cosmet Investig Dermatol.* 2016; 9: 71-77. doi: 10.2147/CCID.S98091.
22. Woo YR, Lim JH, Cho DH, Park HJ. Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition. *Int J Mol Sci.* 2016;17(9):1562. Published 2016 Sep 15. doi:10.3390/ijms17091562.
23. Del Rosso JQ. Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. *Cutis.* 2004;73(1 Suppl):29-33.
24. Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. *J Am Acad Dermatol.* 2015;72(5):761-772. doi:10.1016/j.jaad.2014.08.027
25. Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea. *J Eur Acad Dermatol Venereol.* 2017;31(11):1775-1791. doi:10.1111/jdv.14349.
26. Motofei IG, Rowland DL, Baconi DL, et al. Androgenetic alopecia; drug safety and therapeutic strategies. *Expert Opin Drug Saf.* 2018;17(4):407-412. doi:10.1080/14740338.2018.1430765
27. Two AM, Hata TR, Nakatsuji T, et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. *J Invest Dermatol.* 2014;134(4):1143-1145. doi:10.1038/jid.2013.472.
28. Li X, Guo H, Tian Q, et al. Effects of 5-aminolevulinic acid-mediated photodynamic therapy on antibiotic-resistant staphylococcal biofilm: an in vitro study. *J Surg Res.* 2013;184(2):1013-1021. doi:10.1016/j.jss.2013.03.094.
29. Cecic I, Sun J, Korbelik M. Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells. *Photochem Photobiol.* 2006;82(2): 558-562. doi:10.1562/2005-09-09-RA-681.
30. Lee JB, Bae SH, Moon KR, Na EY, Yun SJ, Lee SC. Light-emitting diodes downregulate cathelicidin, kallikrein and toll-like receptor 2 expressions in keratinocytes and rosacea-like mouse skin. *Exp Dermatol.* 2016;25(12):956-961. doi:10.1111/exd.13133
31. Noborio R, Nishida E, Kurokawa M, Morita A. A new targeted blue light phototherapy for the treatment of acne. *Photodermatol Photoimmunol Photomed.* 2007; 23(1): 32-34. doi: 10.1111/j.1600-0781.2007.00268.x
32. Kumar A, Ghate V, Kim MJ, Zhou W, Khoo GH, Yuk HG. Antibacterial efficacy of 405, 460 and 520 nm light emitting diodes on *Lactobacillus plantarum*, *Staphylococcus aureus* and *Vibrio parahaemolyticus*. *J Appl Microbiol.* 2016; 120(1):49-56. doi: 10.1111/jam.12975.
33. Sorbellini E, De Padova MP, Rinaldi F. Coupled blue and red light-emitting diodes therapy efficacy in patients with rosacea: two case reports. *J Med Case Rep.* 2020;14(1):22. Published 2020 Jan 28. doi:10.1186/s13256-019-2339-6.
34. Handler MZ, Bloom BS, Goldberg DJ. IPL vs PDL in treatment of facial erythema: A split-face study. *J*

- Cosmet Dermatol.* 2017; 16(4): 450-453. doi: 10.1111/jocd.12365
35. Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN, Hong CK. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. *Dermatology.* 2015;230(4):299-301. doi:10.1159/000368773
 36. Feaster B, Cline A, Feldman SR, Taylor S. Clinical effectiveness of novel rosacea therapies. *Curr Opin Pharmacol.* 2019;46:14-18.
 37. Maxwell EL, Ellis DA, Manis H. Acne rosacea: effectiveness of 532 nm laser on the cosmetic appearance of the skin. *J Otolaryngol Head Neck Surg.* 2010;39(3):292-296.
 38. Stanescu AMA, Grajdeanu IV, Iancu MA, et al. Correlation of Oral Vitamin D Administration with the Severity of Psoriasis and the Presence of Metabolic Syndrome. *REVISTA DE CHIMIE.* 2018; 69(7):1668-72.
 39. Stoian Pantea A, Bala C, Rusu A, et al. Gender Differences in the Association of Ferritin and 25-hydroxyvitamin D. *REVISTA DE CHIMIE* 2018; 69(4):864-869.
 40. Kim SJ, Lee Y, Seo YJ, Lee JH, Im M. Comparative Efficacy of Radiofrequency and Pulsed Dye Laser in the Treatment of Rosacea. *Dermatol Surg.* 2017;43(2):204-209. doi:10.1097/DSS.0000000000000968
 41. Scala J, Vojvodic A, Vojvodic P, et al. Botulin Toxin Use in Rosacea and Facial Flushing Treatment. *Open Access Maced J Med Sci.* 2019;7(18):2985-2987. doi:10.3889/oamjms.2019.784
 42. Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. *Exp Dermatol.* 2017;26(8):659-667. doi:10.1111/exd.13143
 43. Tatu AL, Clatici V, Cristea V. Isolation of *Bacillus simplex* strain from *Demodex folliculorum* and observations about *Demodicosis spinulosa*. *Clin Exp Dermatol.* 2016;41(7):818-820. doi:10.1111/ced.12893
 44. Tatu AL, Ionescu MA, Cristea VC. *Demodex folliculorum* associated *Bacillus pumilus* in lesional areas in rosacea. *Indian J Dermatol Venereol Leprol.* 2017;83(5):610-611. doi:10.4103/ijdvl.IJDVL_921_16.
 45. Tatu AL, Nwabudike LC. Reply to: Kubiak K et al. Endosymbiosis and its significance in dermatology. *J Eur Acad Dermatol Venereol.* 2018;32(9):e346-e347. doi:10.1111/jdv.14921
 46. Clanner-Engelshofen BM, French LE, Reinholz M. *Corynebacterium kroppenstedtii* subsp. *demodicis* is the endobacterium of *Demodex folliculorum*. *J Eur Acad Dermatol Venereol.* 2020;34(5):1043-1049. doi:10.1111/jdv.16069
 47. Ardeleanu V, Dobre M, Georgescu EM. Deep Facial Wrinkle Treatment Outcome After First Injection of Reticulated Hyaluronic Acid. *Rev Chim.* 2015; 66(12):2129-2131.
 48. Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. *J Invest Dermatol.* 2011;131(3):688-697. doi:10.1038/jid.2010.351
 49. Merlo EM. Adolescent phobia as a “mask object”. *Mediterranean Journal of Clinical Psychology.* 2019;7(1). doi:10.6092/2282-1619/2019.7.2241
 50. Wang L, Wang YJ, Hao D, et al. The Theranostics Role of Mast Cells in the Pathophysiology of Rosacea. *Front Med (Lausanne).* 2020;6:324. doi:10.3389/fmed.2019.00324
 51. Ardeleanu V, Berbece SI, Florescu IP, Jecan RC. The Use of Hyaluronic Acid Combined with Teosyal Redensity II for the Treatment of Dark Circles Under the Eyes. *Materiale Plastice.* 2017;54(1):37-40.
 52. Vaughn AR, Notay M, Clark AK, Sivamani RK. Skin-gut axis: The relationship between intestinal bacteria and skin health. *World J Dermatol.* 2017; 6(4):52–58. doi:10.5314/wjd.v6.i4.52
 53. Jecan RC, Nicolau A, Florescu IP, Ardeleanu V, Berbece S. Use of Trichloroacetic Acid in Treating Facial Hyperpigmentation. *Materiale Plastice.* 2017; 54(1):88-90.
 54. Ardeleanu V, Sabina Radaschin D, Tatu AL. Excimer laser for psoriasis treatment: A case report and short review. *Exp Ther Med.* 2020;20(1):52-55. doi: 10.3892/etm.2020.8529.
 55. Tatu AL, Radaschin DS, Constantin VD, Stana P, Ardeleanu V. Laser therapy in superficial morphea lesions - indications, limitations and therapeutic alternatives. *J Mind Med Sci.* 2020;7(1):46-51. doi:10.22543/7674.71.P4651